Early, late and very late incidence of bioresorbable scaffold thrombosis: A systematic review and meta-analysis of randomized clinical trials and observational studies

Minerva Cardioangiologica

Volumn 65, Issue 1, 2017, Pages 32-51

  Collet, Carlos ^a   Asano, Taku ^a   Sotomi, Yohei ^a   Cavalcante, Rafael ^b   Miyazaki, Yosuke ^b   Zeng, Yaping ^b   Tummala, Karthik ^c   Stanetic, Bojan ^d   Tijssen, Jan ^a   Dewinter, Robbert ^a   Onuma, Yoshinobu ^b   Capodanno, Davide ^e   Serruys, Patrick W ^f  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Siddhartha Medical College   (India)

^d University Clinical Centre of the Republic Srpska   (Bosnia and Herzegovina)

^e UNIVERSITY OF CATANIA   (Italy)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Meta analysis; Thrombosis; Tissue scaffolds

Indexed keywords

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; BIORESORBABLE SCAFFOLD; CORONARY ARTERY OBSTRUCTION; DYSLIPIDEMIA; FOLLOW UP; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MEDICAL DEVICE COMPLICATION; META ANALYSIS; MITRAL VALVE STENOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PROSTHESIS THROMBOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMATIC REVIEW; TISSUE SCAFFOLD; TRICUSPID VALVE STENOSIS; ADVERSE EFFECTS; BIODEGRADABLE IMPLANT; BLOOD VESSEL PROSTHESIS; OBSERVATIONAL STUDY; THROMBOSIS;

ABSORBABLE IMPLANTS; BLOOD VESSEL PROSTHESIS; HUMANS; OBSERVATIONAL STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOSIS;

EID: 85014484753     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: 10.23736/S0026-4725.16.04238-9     Document Type: Review

References (92)

1. Serruys PW, Strauss BH, Beatt KJ, et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. NEngl J Med. 1991;324(1):13-17.
2. De Jaegere P, Mudra H, Figulla H, et al. Intravascular ultrasound-guided optimized stent deployment. Im-mediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronar-ies Study (MUSIC Study). European heart journal. 1998;19(8):1214-1223.
3. Stone GW, Ellis SG, Cox DA, et al. Apolymer-based, paclitaxel-eluting stent in patients with coronary artery disease. NEngl J Med. 2004;350(3):221-231.
4. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angi-ography and three-dimensional intravascular ultrasound study. Circulation. 2001;103(2):192-195.
5. Joner M, Finn AV, Farb A, et al. Pathology of drug-elut-ing stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48(1):193-202.
6. Palmerini T, Benedetto U, Biondi-Zoccai G, et al. Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evi-dence From a Comprehensive Network Meta-Analysis. J Am Coll Cardiol. 2015;65(23):2496-2507.
7. Serruys PW, Ormiston J, van Geuns RJ, et al. APoly-lactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up. J Am Coll Cardiol. 2016;67(7):766-776.
8. Kimura T, Kozuma K, Tanabe K, et al. Arandomized trial evaluating everolimus-eluting Absorb bioresorb-able scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. European heart journal. 2015;36(47):3332-3342.
9. Ellis SG, Kereiakes DJ, Metzger DC, et al. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Dis-ease. NEngl J Med. 2015;373(20):1905-1915.
10. Stone GW, Gao R, Kimura T, et al. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coro-nary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016;387(10025):1277-1289.
11. Capodanno D, Joner M, Zimarino M. What about the risk of thrombosis with bioresorbable scaffolds? EuroInter-vention. 2015;11 Suppl V:V181-184.
12. Kraak RP, Hassell ME, Grundeken MJ, et al. Initial ex-perience and clinical evaluation of the Absorb bioresorb-able vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCIRegistry. EuroInter-vention. 2015;10(10):1160-1168.
13. Capodanno D, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vas-cular scaffolds in routine clinical practice: early and mid-term outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015;10(10):1144-1153.
14. Serruys PW, Chevalier B, Dudek D, et al. Abioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural second-ary outcomes from a randomised controlled trial. Lancet. 2015;385(9962):43-54.
15. Puricel S, Cuculi F, Weissner M, et al. Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehen-sive Analysis of Clinical Presentation, Mechanisms, and Predictors. J Am Coll Cardiol. 2016;67(8):921-931.
16. Jimenez JM, Davies PF. Hemodynamically driven stent strut design. Annals of biomedical engineering. 2009;37(8):1483-1494.
17. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elabora-tion and explanation. BMJ (Clinical research ed.). 2016;354:i4086.
18. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344-2351.
19. Hoy D, Brooks P, Woolf A, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. Journal of clinical epi-demiology. 2012;65(9):934-939.
20. Ellis SG, Kereiakes DJ, Metzger DC, et al. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Dis-ease. NEngl J Med. 2015;373(20):1905-1915.
21. Chevalier B, Onuma Y, van Boven AJ, et al. Randomised comparison of a bioresorbable everolimus-eluting scaf-fold with a metallic everolimus-eluting stent for ischae-mic heart disease caused by de novo native coronary ar-tery lesions: the 2-year clinical outcomes of the ABSORB IItrial. EuroIntervention. 2016;12(6).
22. Gao R, Yang Y, Han Y, et al. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coro-nary Artery Disease: ABSORB China Trial. J Am Coll Cardiol. 2015;66(21):2298-2309.
23. Puricel S, Arroyo D, Corpataux N, et al. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol. 2015;65(8):791-801.
24. Sabate M, Windecker S, Iniguez A, et al. Everolimus-eluting bioresorbable stent vs. durable polymer everoli-mus-eluting metallic stent in patients with ST-segment el-evation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFIIItrial. European heart journal. 2016;37(3):229-240.
25. Stuijfzand WJ, Raijmakers PG, Driessen RS, et al. Evaluation of myocardial blood flow and coronary flow reserve after implantation of a bioresorbable vascular scaffold versus metal drug-eluting stent: an interim one-month analysis of the VANISH trial. EuroIntervention. 2016;12(5):e584-594.
26. Brugaletta S, Gori T, Low AF, et al. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATIONStudy (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coro-nary stents in the treatment of patients with ST-segment elevation myocardial infarction). JACC Cardiovasc In-terv. 2015;8(1 Pt B):189-197.
27. Fam JM, Felix C, van Geuns RJ, et al. Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocar-dial infarction: a propensity-matched comparison to me-tallic drug eluting stents 18-month follow-up of the BVS STEMI first study. EuroIntervention. 2016;12(1):30-37.
28. FH. Hernandez. REPARA: acute performance from Iberi-an real-world experience (abstr.). Presented at: EuroPCR. Paris, France, 2015.
29. C. Hamm. 30-days-follow-up of the German- Austrian-ABSORB register: GABI-R(abstr.). Presented at: Eu-roPCR. Paris, France, 2015.
30. Seth A. ABSORB FIRST: 1-year clinical outcomes from a prospective, multi-center global registry. Presented at: TCT. San Francisco, the United States, 2015.
31. Ruparelia N. Bioresorbable scaffold and thrombosis: in-sights from the GHOST-EU registry (abstr.). Presented at: EuroPCRParis, France, 2015.
32. Ielasi A, Cortese B, Varricchio A, et al. Immediate and midterm outcomes following primary PCIwith biore-sorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: insights from the multicentre "Registro ABSORB Italiano" (RAIregistry). EuroIntervention. 2015;11(2):157-162.
33. De Ribamar Costa J, Abizaid A. Long-term outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic st-ents: Apropensity score comparison of patients enrolled in the absorb extend and spirit trials. Journal of the Amer-ican College of Cardiology. 2016;(1):430.
34. Rzeszutko L, Siudak Z, Tokarek T, et al. Twelve months clinical outcome after bioresorbable vascular scaffold implantation in patients with stable angina and acute coronary syndrome. Data from the Polish National Reg-istry. Postepy w kardiologii interwencyjnej = Advances in interventional cardiology. 2016;12(2):108-115.
35. Trobs M, Achenbach S, Rother J, Klinghammer L, Schlundt C. Bioresorbable vascular scaffold thrombosis in a consecutive cohort of 550 patients. Catheter Cardio-vasc Interv. 2016.
36. Azzalini L, Al-Hawwas M, L'Allier PL. Very late biore-sorbable vascular scaffold thrombosis: a new clinical en-tity. EuroIntervention. 2015;11(1):e1-2.
37. Gori T, Schulz E, Hink U, et al. Clinical, Angiographic, Functional, and Imaging Outcomes 12 Months After Im-plantation of Drug-Eluting Bioresorbable Vascular Scaf-folds in Acute Coronary Syndromes. JACC Cardiovasc Interv. 2015;8(6):770-777.
38. Felix CM, Fam JM, Diletti R, et al. Mid- to Long-Term Clinical Outcomes of Patients Treated With the Everoli-mus-Eluting Bioresorbable Vascular Scaffold: The BVS Expand Registry. JACC Cardiovasc Interv. 2016.
39. Saad M, Abdin A, Thiele H, et al. Bioresorbable Vascu-lar Scaffolds in a Real-World Patient Population-Results From a Mid-Term Angiographic Follow-Up. J Interv Car-diol. 2016;29(4):341-347.
40. Dalos D. Early outcomes of real-world patients treated with everolimus-eluting bioresorbable vascular scaffolds. Presented at: AsiaPCR/SingLIVE2015, Singapore, Sin-gapore.
41. Sainsous J, Brunet J, Xavier Hager F, et al. 0505: Bi-oresorbable vascular scaffold: preliminary experience of 200 patients and follow up at 18 months of the first 100. Archives of Cardiovascular Diseases Supplements. 2016;8(1):10-11.
42. Suarez De Lezo J, Martin P, Pan M, et al. Bioresorbable Vascular Scaffold for the Treatment of Coronary Bifurca-tion Lesions: Immediate Results and 1-year Follow-up. Rev Esp Cardiol (Engl Ed). 2016;69(6):554-562.
43. Suarez de Lezo J, Martin P, Mazuelos F, et al. Direct bioresorbable vascular scaffold implantation: Feasibil-ity and midterm results. Catheter Cardiovasc Interv. 2016;87(5):E173-182.
44. Costopoulos C, Crowson MC, Brown AJ, et al. Mid-term clinical outcomes of ABSORB bioresorbable vas-cular scaffold implantation in a real-world population: Asingle-center experience. Cardiovascular revascu-larization medicine: including molecular interventions. 2015;16(8):461-464.
45. Costopoulos C, Latib A, Naganuma T, et al. Comparison of early clinical outcomes between ABSORB bioresorb-able vascular scaffold and everolimus-eluting stent im-plantation in a real-world population. Catheter Cardio-vasc Interv. 2015;85(1):E10-15.
46. Schwencke C, Naber C, Wohrle J, et al. Two-year out-comes after bioresorbable scaffold implantation-the mul-ticenter assure registry. Journal of the American College of Cardiology. 2015;1):B207.
47. Raber L, Brugaletta S, Yamaji K, et al. Very Late Scaf-fold Thrombosis: Intracoronary Imaging and Histopatho-logical and Spectroscopic Findings. J Am Coll Cardiol. 2015;66(17):1901-1914.
48. Biscaglia S, Ugo F, Ielasi A, et al. Bioresorbable Scaffold vs. Second Generation Drug Eluting Stent in Long Coro-nary Lesions requiring Overlap: APropensity-Matched Comparison (the UNDERDOGS study). Int J Cardiol. 2016;208:40-45.
49. Nguyen MC, Jepson N, Chia P, et al. PM200 Austral-ian Experience with AbsorbTM Bioresorbable Scaffold Technology in "Real-World" Coronary Disease. Global Heart.9(1):e104.
50. Ozel E, Tastan A, Ozturk A, Ozcan EE, Kilicaslan B, Ozdogan O. Procedural and one-year clinical outcomes of bioresorbable vascular scaffolds for the treatment of chronic total occlusions: a single-centre experience. Car-diovascular journal of Africa. 2016;27:1-5.
51. Ojeda S, Pan M, Romero M, et al. Outcomes and computed tomography scan follow-up of bioresorb-able vascular scaffold for the percutaneous treatment of chronic total coronary artery occlusion. Am J Cardiol. 2015;115(11):1487-1493.
52. Ojeda S, Pan M, Martin P, et al. Patency of coronary side branches covered by an everolimus-eluting biore-sorbable vascular scaffold: Clinical outcomes and com-puted tomography scan follow-up. EuroIntervention. 2016;11(11):e1283-e1290.
53. Latini RA, Granata F, Ielasi A, et al. Bioresorbable vas-cular scaffolds for small vessels coronary disease: The BVS-save registry. Catheter Cardiovasc Interv. 2016.
54. Sengottuvelu G. Procedural and short-term outcomes with the use of bioresorbable scaffold in patients with diabetes mellitus. Presented at: EuroPCRParis, France, 2014.
55. Moscarella E, Ielasi A, Granata F, et al. Long-Term Clini-cal Outcomes After Bioresorbable Vascular Scaffold Im-plantation for the Treatment of Coronary In-Stent Reste-nosis: AMulticenter Italian Experience. Circ Cardiovasc Interv. 2016;9(4):e003148.
56. Haji K, Dick R, Baker L, Waugh S. Bioresorbable scaf-fold stents, single centre experience. Heart Lung and Cir-culation. 2015;24:S264-S265.
57. Teeuwen K, Hubbers S, Tijssen JGP, Van Der Heyden JAS, Rensing BJWM, Suttorp MJ. Experiences with the Absorb everolimus-eluting bioresorbable vascular scaf-fold in all comers: The St. Antonius hospital single centre registry. Clinical Trials and Regulatory Science in Cardi-ology. 2015;10:1-6.
58. Khripun AV, Malevannyi MV, Kulikovskikh Y. Biore-sorbable vascular scaffolds for ST-segment elevation myocardial infarction treatment. European heart journal. 2015;36:414.
59. Jaguszewski M, Ghadri JR, Zipponi M, et al. Feasibility of second-generation bioresorbable vascular scaffold im-plantation in complex anatomical and clinical scenarios. Clin Res Cardiol. 2015;104(2):124-135.
60. Dudek D, Rzeszutko L, Zasada W, et al. Bioresorbable vascular scaffolds in patients with acute coronary syn-dromes: the POLARACS study. Polskie Archiwum Me-dycyny Wewnetrznej. 2014;124(12):669-677.
61. Robaei D, Back LM, Ooi SY, Pitney MR, Jepson N. Everolimus-eluting Bioresorbable Vascular Scaffold Im-plantation in Real World and Complex Coronary Disease: Procedural and 30-day Outcomes at Two Australian Cen-tres. Heart, lung & circulation. 2015;24(9):854-859.
62. Tousek P, Kocka V, Maly M, et al. Long-term follow-up after bioresorbable vascular scaffold implantation in STEMIpatients: PRAGUE-19 study update. EuroInter-vention. 2016;12(1):23-29.
63. Ching M HH, Ooi Y, et al. TCTAP A-079. Clinical Efficacy and Safety of Bioresorbable Vascular Scaffold in an Unselected Patient Population: ASingle Centre Real World Experience. J Am Coll Cardiol. 2014;63(12-S2):S22-S23.
64. Mattesini A, Secco GG, Dall'Ara G, et al. ABSORB bio-degradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance. JACC Cardiovasc Interv. 2014;7(7):741-750.
65. Jamshidi P, Nyffenegger T, Sabti Z, et al. Anovel ap-proach to treat in-stent restenosis: 6- and 12-month re-sults using the everolimus-eluting bioresorbable vascular scaffold. EuroIntervention. 2016;11(13):1479-1486.
66. Wójcik J MA, Wiórkowski K, Jankiewicz M. Bioresorb-able Scaffold As Option For The Treatment Of Coronary In-Stent Restenosis: Result From Single-Centre Prospective Observational Study With Angiographic Follow-Up. J Am Coll Cardiol.2015(66):15-S.
67. Vaquerizo B, Barros A, Pujadas S, et al. One-Year Results of Bioresorbable Vascular Scaffolds for Coronary Chron-ic Total Occlusions. Am J Cardiol. 2016;117(6):906-917.
68. Lesiak M, Lanocha M, Araszkiewicz A, et al. Percutane-ous coronary intervention for chronic total occlusion of the coronary artery with the implantation of bioresorb-able everolimus-eluting scaffolds. Poznan CTO-Absorb Pilot Registry. EuroIntervention. 2016;12(2):e144-151.
69. Liang M, Kajiya T, Lee CH, et al. Initial experience in the clinical use of everolimus-eluting bioresorbable vas-cular scaffold (BVS) in a single institution. Int J Cardiol. 2013;168(2):1536-1537.
70. Kochman J, Tomaniak M, Pietrasik A, et al. Bioresorb-able everolimus-eluting vascular scaffold in patients with ST-segment elevation myocardial infarction: Optical co-herence tomography evaluation and clinical outcomes. Cardiology journal. 2015;22(3):315-322.
71. Biryukov A, Ivanchenko R, Kaputin M. Short-term clini-cal outcomes for bifurcation treatment using a provision-al T-stenting and double proximal optimization technique with absorb bioresorbable scaffolds. Journal of the Amer-ican College of Cardiology. 2015;1):C163.
72. West N. BA, McCormick L., Braganza D., Hoole S. Initial clinical experience with the bioresorbable vascular scaffold in a selected real-world population including calcified lesions, unprotected bifurcations and ACS (STEMI& NSTEMI) cases. Presented at: EuroPCRParis, France, 2013.
73. Rohit M, Patodia A. Optical coherence tomography guided assessment of outcomes after implantation of bi-oresorbable stents at mid term follow-up in Indian pa-tients. Journal of the American College of Cardiology. 2016;1):S22-S23.
74. Kajiya T, Liang M, Sharma RK, et al. Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI). EuroIntervention. 2013;9(4):501-504.
75. May AN, Carlyle A, Pitney M, Ooi SY, Jepson N. PT187 Bioresorbable scaffolds in the treatment of chronic total occlusions (CTO). Global Heart.9(1):e204.
76. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379(9824):1393-1402.
77. Airoldi F, Colombo A, Morici N, et al. Incidence and pre-dictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation. 2007;116(7):745-754.
78. Van Werkum JW, Heestermans AA, Zomer AC, et al. Predic-tors of coronary stent thrombosis: the Dutch Stent Throm-bosis Registry. J Am Coll Cardiol. 2009;53(16):1399-1409.
79. Gori T, Jansen T, Weissner M, et al. Coronary evagina-tions and peri-scaffold aneurysms following implantation of bioresorbable scaffolds: incidence, outcome, and op-tical coherence tomography analysis of possible mecha-nisms. European heart journal. 2015.
80. Brie D, Penson P, Serban MC, et al. Bioresorbable scaf-fold - Amagic bullet for the treatment of coronary artery disease? Int J Cardiol. 2016;215:47-59.
81. Raber L, Magro M, Stefanini GG, et al. Very late coro-nary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation. 2012;125(9):1110-1121.
82. Tandjung K, Sen H, Lam MK, et al. Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience Vstents: 2-year follow-up of the randomized TWENTEtrial. J Am Coll Cardiol. 2013;61(24):2406-2416.
83. Meincke F, Spangenberg T, Heeger CH, Bergmann MW, Kuck KH, Ghanem A. Very Late Scaffold Thrombosis Due to Insufficient Strut Apposition. JACC Cardiovasc Interv. 2015;8(13):1768-1769.
84. Ielasi A, Cortese B, Steffenino G. Late Structural Dis-continuity as a Possible Cause of Very Late Everolimus-Eluting Bioresorbable Scaffold Thrombosis. JACC Car-diovasc Interv. 2015;8(10):e171-172.
85. Lipinski MJ, Escarcega RO, Baker NC, et al. Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold: ASys-tematic Review and Meta-Analysis. JACC Cardiovasc Interv. 2016;9(1):12-24.
86. Banach M, Serban MC, Sahebkar A, et al. Comparison of clinical outcomes between bioresorbable vascular stents versus conventional drug-eluting and metallic stents: a systematic review and meta-analysis. EuroIntervention. 2016;12(2):e175-189.
87. Bangalore S, Toklu B, Bhatt DL. Outcomes with bio-absorbable vascular scaffolds versus everolimus eluting stents: Insights from randomized trials. Int J Cardiol. 2016;212:214-222.
88. Mukete BN, van der Heijden LC, Tandjung K, et al. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: Asystematic review and meta-analysis of studies. Int J Car-diol. 2016;221:1087-1094.
89. Kang SH, Chae IH, Park JJ, et al. Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials. JACC Cardiovasc Interv. 2016.
90. Cassese S, Byrne RA, Ndrepepa G, et al. Everoli-mus-eluting bioresorbable vascular scaffolds ver-sus everolimus-eluting metallic stents: a meta-anal-ysis of randomised controlled trials. The Lancet. 2016;387(10018):537-544.
91. Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary interven-tion and stenting in the TRITON-TIMI38 trial: a subanal-ysis of a randomised trial. Lancet. 2008;371(9621):1353-1363.
92. Cuculi F, Puricel S, Jamshidi P, et al. Optical Coher-ence Tomography Findings in Bioresorbable Vascu-lar Scaffolds Thrombosis. Circ Cardiovasc Interv. 2015;8(10):e002518.